Director, Policy & Advocacy Multidisciplinary Association for Psychedelic Studies (MAPS) Berkeley, California
Psychedelic agents such as psilocybin and MDMA may become FDA-approved treatments for mental health and addiction, so what does that mean to modern psychiatry? In this session, expert faculty will discuss how the approval of these agents could be integrated into current clinical practice standards.